Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701479 | 0.87 | KDR (0.74) | EPHX2KDRHTR2AKCNH2MEN1 | |
| SCHEMBL6815425 | 0.83 | KDR (0.68) | EPHX2KDRHTR2AKCNH2POLB | |
| SCHEMBL11926259 | 0.82 | EPHX2 (0.69) | EPHX2POLBTP53RAB9AMEN1 | |
| SCHEMBL385247 | 0.81 | KDM4E (0.62) | EPHX2SMN1; SMN2TP53CYP2C9CYP2C19 | |
| SCHEMBL6814510 | 0.81 | KDR (0.62) | EPHX2KDRHTR2AKCNH2POLB | |
| SCHEMBL15459823 | 0.81 | ALDH1A1 (0.67) | EPHX2SMN1; SMN2TP53CYP2C9CYP2C19 | |
| SCHEMBL4702962 | 0.80 | EPHX2 (0.55) | EPHX2KDRHTR2AKCNH2 | |
| SCHEMBL13701717 | 0.79 | EPHX2 (0.63) | EPHX2KDRHTR2AKCNH2LMNA | |
| SCHEMBL4265258 | 0.79 | EPHX2 (0.89) | EPHX2 | |
| SCHEMBL4698008 | 0.77 | KDM4E (0.70) | EPHX2POLBSMN1; SMN2TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926737-B1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-15 | — | — | EP | disclosed |
| EP-1926737-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031428-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BARTKOVITZ DAVID J | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BRAF, RAF1, MAP3K7 | EPHX2 2946/4885KDR 982/4885HTR2A 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.